Noticias & Medios

• Comunicado de prensa
• Eventos

Comunicado de prensa

Flux RSS

bioMérieux press releases and news items are sorted by theme (Clinical, Industry and Corporate) and by date.

April 8, 2010 PREVI™ Isola ganó el premio 2010 de Excelencia en Diseño Médico The award highlights the automated media streaker’s breakthrough technology. A world leader in in vitro diagnostics, bioMérieux announced today that its automated media streaker, PREVI™ Isola has received a 2010 Medical Design Excellence Award for contributions and advances in the design of medical products. This exclusive award recognizes products for their design and engineering features, including user-related functions that improve healthcare delivery and change traditional medical attitudes or practices. PREVI Isola was designed to revolutionize front-end media processing tasks, and it is a critical component in bioMérieux’s complete range of solutions and services for Full Microbiology Lab Automation (FMLA™): www.biomerieux-diagnostics.com/fmla Más

January 7, 2010 Philips and bioMérieux announce partnership to develop and market next-generation handheld diagnostic solutions for Point-of-Care Fully automated handheld diagnostic test devices designed to improve diagnosis and disease management in critical care settings within hospitals. Royal Philips Electronics (NYSE: PHG, AEX: PHI) and bioMérieux (NYSE Euronext: BIM) today announced that they have signed an agreement to jointly develop fully automated handheld diagnostic testing solutions for hospital use that can be deployed at the point-of-care – i.e. close to the patient. The collaboration aims to improve diagnosis and management of disease in critical care settings within hospitals (for example, Emergency Departments, Coronary Units and Intensive Care Units (ICUs)). Más

Novembre 20, 2009 bioMérieux’s VIDAS® System Simplifies the Detection of Salmonella & E. coli O157 Including H7 Strains for the Meat Industry Marcy l'Etoile, France - November 10, 2009. bioMérieux, a world leader in the field of in vitro diagnostics, today announced that VIDAS® Salmonella Xpress (SLMX) and VIDAS® UP E. coli O157 (Including H7) kits have been validated by AFNOR Certification according to the ISO 16140 standard. These validations cover the testing of raw beef and veal Más

November 17, 2009 bioMérieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer Treatment bioMérieux has signed an agreement with GlaxoSmithKline to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer patients. This test, based on emerging biomarkers, will be intended for use in both adjuvant and metastatic breast cancer settings, subject to regulatory approvals. Over 500,000 new cases of breast cancer are diagnosed each year in the US and Europe alone and predictive tests have been shown to improve outcomes for these patients. Más

November 10, 2009 bioMérieux’s VIDAS® System Simplifies the Detection of Salmonella & E. coli O157 Including H7 Strains for the Meat Industry bioMérieux, a world leader in the field of in vitro diagnostics, today announced that VIDAS® Salmonella Xpress (SLMX) and VIDAS® UP E. coli O157 (Including H7) kits have been validated by AFNOR Certification according to the ISO 16140 standard. These validations cover the testing of raw beef and veal. Más

November 6, 2009 bioMérieux Launches a Molecular Diagnostic MRSA Test on its EasyQ® Automated Platform Methicillin Resistant Staphylococcus aureus (MRSA) is the most prevalent multi-drug resistant bacteria and a growing threat to health. bioMérieux, a world leader in the field of in vitro diagnostics, today launched NucliSENS EasyQ® MRSA, a new automated test for Methicillin Resistant Staphylococcus aureus (MRSA), one of the leading causes of healthcare-associated infections. NucliSENS EasyQ MRSA is CE marked and bioMérieux will be submitting for 510(k) approval with the U.S. Food and Drug Administration in the first half of 2010. Más

Noviembre 3, 2009 Alain Pluquet's appointment A world leader in the field of in vitro diagnostics, bioMérieux has appointed Alain Pluquet to the newly created position of Chief Technology Officer (CTO). Más

October 28, 2009 chromIDTM MRSA Launched in U.S. bioMérieux Adds Methicillin-resistant Staphylococcus aureus (MRSA) Screening Tool to its Arsenal Chromogenic media provides cost-effective MRSA identification for hospitals and labs. Más

October 20, 2009 bioMérieux - Business Review for the nine months ended September 30, 2009 2009 Nine-Month Sales up 7.8% at constant exchange rates and scope of consolidation up 11.2% at constant exchange rates, including business development agreements Más

September 24, 2009 bioMérieux Creates New Facility Specialized in the Production of Custom Culture Media for use in Industrial Microbiology Laboratories bioMérieux, a world leader in in vitro diagnostics and leader in microbiological control, has stepped up its production capacity for custom culture media by building a dedicated production unit in Craponne (France), where the company’s main culture media production center is located. Más

September 23, 2009 2nd World HAI Forum: Experts Discuss Looming Threats to Patient Safety Newly evolved enzymes make some bacteria resistant to all common antibiotics Healthcare workers slow to receive flu vaccines Countries not doing enough to combat “superbugs” About 7 million Healthcare-Associated Infections (HAIs) in the U.S. and Europe each year According to a meeting of over 60 infectious disease experts, the global medical community must act on three imminent threats to patients across the world. First threat: common bacteria, such as Escherichia coli (E. coli) are now producing enzymes which make the bacteria capable of de-activating all but the antibiotics that specialists reserve as a last line of defense. Second threat: healthcare workers themselves may be contributing to the spread of infections by failing to get flu vaccinations and, in some countries, coming to work when they are ill rather than taking sick days. Third threat: Health ministries are failing to adopt proven health policies that could limit the spread of infections in hospitals and other healthcare establishments. Más

September 9, 2009 First-Half 2009 Results Growth in sales: 10.3 % - At constant exchange rates, including business development agreements 6.0 % - At constant exchange rates and scope of consolidation Growth in operating results before non-recurring items: 16 % Más

July 24, 2009 bioMérieux - First-Half 2009 Business Review First-Half 2009 Sales Up 6% at constant exchange rates and scope of consolidation Up 10.3% at constant exchange rates, including business development agreements Más

July 24, 2009 bioMérieux is Adapting Production to Support Global Vaccine Production Effort in the Fight Against Influenza A/H1N1 bioMérieux, a world leader in in vitro diagnostics, is increasing its production to support the global effort to fight the Influenza pandemic. The company’s culture media for sterility testing* is used by vaccine manufacturers during the quality control of their production process to help ensure product safety. Sterility testing is critical for the control and release of vaccines on the market. Más

Julio, 2009 NucliSENS EasyQ® HIV-1 v2.0 bioMérieux presenta la prueba molecular NucliSENS EasyQ® HIV-1 v2.0 que mejora el tratamiento de los pacientes portadores de VIH La nueva prueba puede combinarse con la primera técnica de mancha de sangre seca, homologada con marca CE, para cuantificar la carga viral, posibilitando el diagnóstico en zonas alejadas. Más

June 30, 2009 bioMérieux Launches VIDAS® EBV, a New Test for the Diagnosis of Infectious Mononucleosis bioMérieux, a world leader in the field of in vitro diagnostics, today launched VIDAS® EBV for the detection of the Epstein-Barr virus (EBV). This virus causes 80% of cases of infectious mononucleosis, which is often known as “the kissing disease” because it is transmitted through saliva. Más

June 11, 2009 Communiqué de mise à disposition du document de référence au 31 décembre 2008 Le Document de référence 2008 de la Société peut être consulté sur le site Internet de l’Autorités des Marchés Financiers (www.amf-france.org) et sur le site Internet de la Société (www.biomerieux.com). Más

June 10, 2009 Communiqué de mise à disposition du rapport financier annuel modifié au 31 décembre 2008 Más

June 8, 2009 bioMérieux Launches DiversiLab® Saccharomyces DNA Fingerprinting Kit New Molecular Strain Typing Test to Ensure Consistent Quality of Beer. bioMérieux, a world leader in the field of in vitro diagnostics, has launched the DiversiLab® Saccharomyces DNA Fingerprinting kit, which will accurately and reproducibly identify the strain type of yeast used in the brewing of beer. Más

June 1, 2009 Data from Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting - THEROS CancerTYPE ID® predicts cancer origin with 75 percent accuracy in patients whose primary cancer was “unknown” using traditional diagnostics. - bioTheranostics, a bioMérieux company that discovers, develops and commercializes new molecular diagnostic tests in oncology, announced that a recent study demonstrated the company’s THEROS CancerTYPE ID® molecular diagnostic test predicted cancer origin with 75 percent accuracy in patients whose primary cancer was initially “unknown” using traditional diagnostics. Findings were presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fl. Más

May 19, 2009 bioMérieux Launches Molecular Biology Test, NucliSENS EasyQ® HIV-1 v2.0, for Improved Care of Patients with HIV New test can be used with the first CE marked Dry Blood Spot sample collection technique for viral load monitoring, bringing testing to patients in remote locations bioMérieux, a world leader in the field of in vitro diagnostics, presented the latest addition to its HIV testing offer at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). NucliSENS EasyQ® HIV-1 v2.0 is a test able to detect even very low viral load levels in AIDS patients, offering one of the highest degrees of sensitivity available today. Más

May 15, 2009 bioMérieux: Enhancing the Productivity of Microbiology Laboratories with the LeanSigma® Method bioMérieux, a world leader in the field of in vitro diagnostics, is building upon its Full Microbiology Lab Automation™ (FMLA) concept by offering a new tool to its customers, LeanSigma® - today’s most recognized process and flow improvement methodology. Más

May 12, 2009 2009 ESCMID/bioMérieux Research Grant in Clinical Microbiology Winner Conducting Research on Major Cause of Healthcare-Associated Infections bioMérieux, a world leader in in vitro diagnostics, and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announce the recipient of their 2009 Research Grant, which recognizes excellence and major contributions to progress in the field of clinical microbiology by a young scientist from Eastern Europe. Más

April 30, 2009 Communiqué de mise à disposition du rapport financier annuel au 31 décembre 2008 La Société annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son rapport financier annuel au 31 décembre 2008. Más

April 23, 2009 First-Quarter 2009 Business Review: Sales Growth in Line with Objectives Up 6.4% - At constant exchange rates and scope of consolidation. Up 10.6% - At constant exchange rates, including business development agreements. bioMérieux, a global leader in the field of in vitro diagnostics, released its quarterly business review through March 31, 2009. As of March 31, 2009, net sales amounted to €286 million, up 6.4% at constant exchange rates and scope of consolidation (on a like-for-like basis) versus the first quarter of 2008. Factoring in sales related to business development agreements, the increase was 10.6% at constant exchange rates. Más

April 7, 2009 bioMérieux Unveils its Groundbreaking Culture Media Range for Sterility Control of Aseptic Pharmaceutical Plants New range will simplify testing for the pharmaceutical industry. bioMérieux, a world leader in the field of in vitro diagnostics and a leading provider of microbiological solutions for the pharmaceutical industry, launches two innovative culture media for Media Fill Tests (MFT): TSB 3PTM with Animal Peptones and TSB 3PTM with Vegetable Peptones and a color indicator to enhance efficiency and reduce potential errors. Más

March 16, 2009 bioMérieux - 2008 Financial Results The Board of Directors of bioMérieux, a global leader in the field of in vitro diagnostics, met on Friday, March 13 to approve the consolidated financial statements for the year ended December 31, 2008. The meeting was chaired by Alain Mérieux and attended by the Statutory Auditors. Strong sales growth: +9.8%, at constant exchange rates, including business development Improved operating margin before non recurring-items at 16.8% of sales Substantial R&D and manufacturing investments Three strategic acquisitions and expansion of international network Más

January 20, 2009 bioMérieux - 2008 Business Review bioMérieux, a global leader in the field of in vitro diagnostics, released its business review for fourth-quarter and full-year 2008. 2008 Sales Up 7.5% at constant exchange rates and scope of consolidation (like-for-like) Up 9.8% at constant exchange rates, including business development agreements Más

January 15, 2009 bioMérieux’s New TEMPO® Solution Delivers Rapid Results on Direct Enumeration of Yeast and Molds to Improve Food Safety bioMérieux, a world leader in the field of in vitro diagnostics, is enhancing its TEMPO® line for food quality with the launch of one of the most rapid automated solutions for direct enumeration of yeast and mold. TEMPO YM delivers final results in half the time versus most other methods, including the ISO reference method (ISO 21527). Más

December 22, 2008 Appointment of Alexandre Mérieux by the bioMérieux Board of Directors At the meeting of the bioMérieux Board of Directors held on December 19, 2008, Alexandre Mérieux was appointed as “Directeur Général Délégué” of the Company. Stéphane Bancel continues to be responsible for all functions in his role as Chief Executive Officer and to chair the bioMérieux Management Committee. Más

December 14, 2008 Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium Independent studies validate the utility of Theros BCISM for improving risk stratification of early stage breast cancer patients. Más

December 8, 2008 bioMérieux Acquires Culture Media Specialist PML Microbiologicals bioMérieux’s recurring sales will be boosted by expanded reagent range bioMérieux, a world leader in the field of in vitro diagnostics has acquired PML Microbiologicals Inc., a leading provider of culture media and microbiological products in North America for both clinical and industrial applications. This privately held American in vitro diagnostics company has manufacturing and marketing teams based in Portland, Oregon and Toronto, Canada. Más

October 28, 2008 bioMérieux Business review for the nine months ended September 30, 2008 bioMérieux, a global leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2008. Más

October 23, 2008 bioMérieux Opens a Subsidiary in the Middle East, Continuing its International Growth bioMérieux, a world leader in the field of in vitro diagnostics, announces the opening of a subsidiary in the United Arab Emirates. A hub for its operations in the Middle East, bioMérieux’s 39th subsidiary will be based in Dubai. Más

October 14, 2008 bioMérieux Receives Prestigious Frost & Sullivan 2008 North American Market Leadership Award for Pharmaceutical Microbiology - bioMérieux recognized for outstanding strategic vision in U.S. Rapid Pharmaceutical Manufacturing Microbiology Tests Market bioMérieux, a world leader in the field of in vitro diagnostics, is proud to announce that it is the recipient of the Frost & Sullivan 2008 North American Market Leadership Award for Pharmaceutical Microbiology. bioMérieux received an overall score of 10.13 out of a possible 12.00 points, the highest overall Frost & Sullivan Competitive Metrics Score in the U.S. Rapid Pharmaceutical Manufacturing Microbiology Tests Market. The Market Leadership Award is given to a company that displays overall excellence in the market leadership process, including the identification of market challenges, drivers and restraints, brand recognition as well as strategy development and methods of addressing market trends. Más

September 25, 2008 bioMérieux to Develop New Highly-Specific, Non-invasive Test for Prostate Cancer, Reducing Unnecessary Biopsies Prostate cancer is the most prevalent cancer in the United States and the 4th most common worldwide. The combination of a test for a new prostate cancer biomarker, Annexin 3, with the standard screening methods could potentially reduce the number of biopsies conducted by up to 75%, when compared with current screening methods alone. Más

September 11, 2008 bioMérieux Gains Critical Oncology and Theranostics Capabilities with the Acquisition of Molecular Diagnostics Company AviaraDx bioMérieux, a world leader in the field of in vitro diagnostics has acquired the privately held AviaraDx, Inc., a molecular in vitro diagnostics company, based in San Diego, California (USA). AviaraDx’s diagnostic tests, based on their proprietary technologies, are used in the molecular classification of cancers and to assist oncologists in making critical therapeutic decisions. The company has built a molecular R&D lab and a small sales & marketing team, as well as a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified service lab. Más

September 1, 2008 Steve Harbin's appointment A world leader in the field of in vitro diagnostics, bioMérieux has appointed Steve Harbin as Corporate Vice President, Quality Management Systems, Health, Safety and Environment and Internal Control, effective July 15, 2008. Más

July 23, 2008 bioMérieux - First-Half 2008 Review bioMérieux, a global leader in the field of in vitro diagnostics, today released its interim review for the six months ended June 30, 2008. Más

Julio 23,2008 bioMérieux – Haciendo que las pruebas de VIH sean accesibles para todos. Las pruebas de tamizaje diagnóstico y de seguimiento de carga viral juegan un papel importante en la detección temprana y manejo de infecciones por VIH. Estas pruebas hacen posible prevenir posibles transmisiones y mejoran el cuidado del paciente mediante el seguimiento constante y el inicio oportuno del tratamiento. Más

Julio de 2008 BIOMÉRIEUX: LÍDER MUNDIAL EN LA LUCHA CONTRA LAS INFECCIONES HOSPITALARIAS bioMérieux, líder mundial en el campo del diagnóstico in vitro, propone la oferta más completa del mercado para ayudar a hospitales y establecimientos sanitarios a luchar contra las infecciones nocosomiales. Más

Julio de 2008 bioMérieux – Acceso para todos a las pruebas de VIH Las pruebas de carga viral para el diagnóstico desempeñan un papel crítico en la detección temprana y el manejo de las infecciones por VIH. Estas pruebas permiten prevenir que prosiga la transmisión a otras personas y mejorar la atención al paciente mediante un seguimiento regular y el inicio oportuno del tratamiento. Más

June 18, 2008 bioMérieux Increases its Lead in Microbiology with the Acquisition of the Swedish Diagnostics Specialist AB BIODISK. Company’s Etest® will enhance bioMérieux’s high medical-value offer. bioMérieux, a world leader in the field of in vitro diagnostics has concluded an agreement to acquire the privately held AB BIODISK, a Swedish in vitro diagnostics company with facilities for research and development, manufacturing and marketing located in Stockholm. This is bioMérieux’s fourth acquisition in under two years. Más

June 12, 2008 Christian Bréchot Appointed to bioMérieux’s Board Professor Christian Bréchot has been appointed to the Board of Directors of bioMérieux S.A. during its Annual Shareholder’s Meeting, held on June 12th. Más

June 12, 2008 bioMérieux Launches Two Innovative Solutions to Detect Food-Borne Pathogens: chromID™ Sakazakii and chromID™ Vibrio bioMérieux, a world leader in the field of in vitro diagnostics, is enhancing its line of food safety solutions with the launch of two innovative chromogenic culture media, chromID™ Sakazakii and chromID™ Vibrio. Más

May 29, 2008 bioMérieux Unveils Full Microbiology Laboratory Automation Solutions Automation Suite to be showcased at American Society of Microbiology (ASM) in Boston bioMérieux, a world leader in the field of in vitro diagnostics, will unveil a new suite of “Full Microbiology Laboratory Automation” solutions at the 108th General Meeting of the American Society for Microbiology (ASM), held June 1-5 in Boston. bioMérieux believes that full microbiology laboratory automation is imperative to streamlining operations and making more reliable results available faster, particularly in light of the growing threat of healthcare-associated infections. Enhanced automation offsets an increasing lack of specialized personnel, contributing to the control of healthcare expenditures. Más

May 15, 2008 bioMérieux and FIND to Collaborate on Infectious Disease Diagnostics bioMérieux, a leader in the field of in vitro diagnostics and FIND (the Foundation for Innovative New Diagnostics), a Swiss non-profit foundation, have signed a Memorandum of Understanding to jointly undertake development projects in the field of infectious disease diagnostics. Más

April 29, 2008 bioMérieux - First Quarter 2008 Business Review Sales up 6.2% like-for-like. Más

April 15, 2008 bioMérieux Bestowed 2007 Frost & Sullivan European Healthcare-Associated Infection Control Technology Leadership Award Más

April 3, 2008 University of Sunderland and bioMérieux Collaborate in New Research Significantly Improving the Identification of Pseudomonas aeruginosa. A Major Cause of Death in Cystic Fibrosis Patients A team of researchers from the University of Sunderland and bioMérieux, a leading company in the field of in vitro diagnostics, have achieved a new step in the fight against Pseudomonas aeruginosa, a bacterium responsible for deadly healthcare-associated infections, which kills tens of thousands of people throughout the world every year .1 Más

Abril 01, 2008 SEPSIS La sepsis es un síndrome clínico complejo que se define como una respuesta inflamatoria sistémica del cuerpo hacia una infección. Es la causa mas común de muerte en las área de Cuidados Intensivos No Coronarios en donde la mortalidad alcanza valores entre el 32 al 54 % en caso de sepsis severa y choque séptico, respectivamente. Más

March 17, 2008 bioMérieux and Hitachi High-Technologies Corporation Enter into Long-Term Strategic Partnership Focus on Microbiology and Molecular Diagnostics bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics has entered into a long-term strategic partnership with Hitachi High-Technologies Corporation of Japan. Más

March 17, 2008 2007 Financial Results 2007: Clear improvement in growth and in operating margin before non-recurring items Más

March 13, 2008 FDA Clears bioMérieux’s VIDAS® NT-proBNP A High Medical Value Test for Diagnosis of Heart Failure bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, has received 510(k) clearance from the U.S. Food and Drug Administration to market VIDAS® NT-proBNP, a test that helps the diagnosis of heart failure. Más

March 6, 2008 bioMérieux Opens New Subsidiary in Singapore bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, announces the opening of a subsidiary in Singapore. This 38th subsidiary is another milestone for the company’s international expansion. It will also advance bioMérieux’s Asian development strategy, following recent announcements of joint ventures in China and Japan. Más

February 26, 2008 bioMérieux’s Food Safety Handbook is Now Available bioMérieux, a world leader in industrial microbiology control, announces that the first Food Safety Handbook: Microbiological Challenges is now available for food professionals. Published by bioMérieux Editions, the handbook was developed with contributions from 24 internationally renowned experts. Más

February 14, 2008 bioMérieux and Wescor Bring a New Gram Staining Instrument for Enhanced Microbiology Laboratory Workflow bioMérieux (Euronext: BIM) and Wescor, an ELITech Group Company have signed an agreement by which bioMérieux will become Wescor’s exclusive worldwide partner for marketing two customized slide stainer instruments for Gram and tuberculosis bacillus under the bioMérieux brand. Más

January 31, 2008 bioMérieux and Shanghai Kehua Bio-engineering Build Joint Venture Shanghai Kehua Bio-engineering (Stock Code: 002022) and bioMérieux (Euronext: BIM) announce the creation of a Shanghai-based joint venture to which bioMérieux will transfer microplate immunoassay manufacturing currently located at its Boxtel site in the Netherlands. Más

January 22, 2008 2007 Business Review - 2007: sales up 7.4% like-for-like Más

January 15, 2008 Quidel and bioMérieux Announce a Global Strategic Alliance in Rapid Diagnostics Quidel Corporation (NASDAQ: QDEL) and bioMérieux (Euronext: BIM) have agreed to form a long-term global alliance in the area of rapid clinical diagnostics for the point-of-care. bioMérieux will become Quidel’s primary distributor for its QuickVue® rapid diagnostic tests outside the United States and the two companies intend to co-develop new rapid tests using Quidel’s market leading rapid test development capability and bioMérieux’s expertise and extensive library of antibodies and antigens. The companies will especially leverage their mutual expertise in the area of infectious diseases. Más

January 10, 2008 Sysmex and bioMérieux Form a Commercial Joint Venture for the Japanese In Vitro Diagnostics Market Sysmex Corporation (HQ: Kobe, Japan; President: Hisashi Ietsugu) and bioMérieux (Euronext: BIM) announce they have signed an agreement by which Sysmex will take a 34% equity stake in bioMérieux Japan, Ltd. Más

January 8, 2008 bioMérieux Transfers Certain R&D and Manufacturing Activities to France bioMérieux (Euronext: BIM) announces the transfer to France of R&D and certain manufacturing activities currently at its Boxtel site in the Netherlands. The transfer will take place gradually until the end of 2009, when this site closes. Más